Prostate cancer is a leading malignancy among men. Early prostate cancer is most
commonly treated with radical surgery and radiotherapy. In the era of prostate-specific
antigen and newly emerging highly specific screening tests, a greater number of men are
given a diagnosis earlier in life, and disease is more often confined. Less-invasive
treatments, such as focal therapy, are becoming increasingly popular, yielding shorter
hospital stays, faster recovery, and fewer complications. Potential drawbacks to focal therapy …